The role of CUDC‐907, a dual phosphoinositide‐3 kinase and histone deacetylase inhibitor, in inhibiting proliferation of adult T‐cell leukemia

Abstract Objectives New effective therapeutic strategies for human T‐cell leukemia virus type 1 (HTLV‐1)‐driven adult T‐cell leukemia (ATL) are required because of resistance to chemotherapeutic agents. Here, we aimed to determine the therapeutic efficacy of a dual phosphoinositide 3 kinase (PI3K)/histone deacetylase (HDAC) inhibitor, CUDC‐907. Methods Cell viability, cell cycle progression, and apoptotic events were examined by WST‐8 assay, flow cytometry, and Hoechst 33342 staining. Caspase activity was determined using Calorimetric Caspase Assay kits. Immunoblotting and electrophoretic mobility shift assay were used to assess the intracellular signaling cascades. Results The combination of PI3K inhibitor BKM120 and HDAC inhibitor LBH589 resulted in a synergistic cytotoxic effect in HTLV‐1‐infected T cells. CUDC‐907 was more efficacious than BKM120 and LBH589. It induced G 1 cell cycle arrest with downregulation of cyclin D1/D2, CDK4/6, c‐Myc, and phosphorylated retinoblastoma protein expression. Apoptosis was induced via caspase‐3/8/9 activation along with downregulation of Bcl‐X L , Bcl‐2, XIAP, survivin, and cIAP1/2, and upregulation of Bax and Bak. Histone H3 acetylation, H2AX activation, Hsp27 phosphorylation, and Hsp70 and Hsp27 upregulation were observed after treatment. CUDC‐907 suppressed Akt, NF‐κB, and AP‐1 by downregulating phosphorylated and/or total Akt, IKKα/β, RelA, JunB, and JunD. Conclusion CUDC‐907 may be a potential therapeutic agent for ATL.